Egyesült Államok - angol - NLM (National Library of Medicine)

sagent pharmaceuticals - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml

Egyesült Államok - angol - NLM (National Library of Medicine)

onco therapies limited - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 6 mg in 1 ml

Egyesült Államok - angol - NLM (National Library of Medicine)

bluepoint laboratories - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection, usp is indicated in combination with cisplatin. paclitaxel injection, usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors ( see clinical studies: breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. paclitaxel injection, usp, in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. paclitaxel injection, usp is indicated for the second-line treatment of aids-related kaposi's sarcoma. paclitaxel is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in polyoxyl 35 castor oil. paclitaxel should not be used in patients with solid tumors who have baseline neutrophil counts of <1,500 cells/mm 3 or in patients with aids-related kaposi's sarcoma with baseline neutrophil counts of <1,000 cells/mm 3 .

Egyesült Államok - angol - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection, usp is indicated in combination with cisplatin. paclitaxel injection, usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included

Egyesült Államok - angol - NLM (National Library of Medicine)

alembic pharmaceuticals limited - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel injection, usp is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. as first-line therapy, paclitaxel injection, usp is indicated in combination with cisplatin. paclitaxel injection, usp is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. in the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptor-negative tumors (see clinical studies, breast carcinoma ). paclitaxel injection, usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-ga is indicated for: primary treatment of ovarian cancer in combination with a platinum agent.; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-ga is indicated for: * primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-ga is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy. * adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. * treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-ga is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - paclitaxel 6 mg/ml;   - concentrate for infusion - 6 mg/ml - active: paclitaxel 6 mg/ml   excipient: ethanol polyoxyl 35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic ovarian cancer after failure of standard therapy.